The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Current and next generation influenza vaccines: Formulation and production strategies
Open accessAbstract
Vaccination is the most effective method to prevent influenza infection. However, current influenza vaccines have several limitations. Relatively long production times, limited vaccine capacity, moderate efficacy in certain populations and lack of cross-reactivity are important issues that need to be addressed. We give an overview of the current status and novel developments in the landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel vaccine concepts not only depends on immunological or clinical outcomes, but also depends on biotechnological aspects, such as formulation and production methods, which are frequently overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies ahead in the influenza vaccine field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z., Qiu, H., Xu, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304459 · Cited by 2,310
Emergence and pandemic potential of swine-origin H1N1 influenza virus
Neumann, G., Noda, T., & Kawaoka, Y. (2009) · Nature · doi:10.1038/nature08157 · Cited by 1,561
Wilkinson, T. M., Li, C. K. F., Chui, C. S. C., Huang, A. K. Y., Perkins, M., Liebner, J. C., Lambkin-Williams, R., Gilbert, A., Oxford, J., Nicholas, B., et al. (2012) · Nature Medicine · doi:10.1038/nm.2612 · Cited by 974
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C.-J., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 885
Cellular immune correlates of protection against symptomatic pandemic influenza
Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T., Barclay, W., Deeks, J. J., & Lalvani, A. (2013) · Nature Medicine · doi:10.1038/nm.3350 · Cited by 862
Large-scale manufacture of peptide therapeutics by chemical synthesis
Bray, B. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1133 · Cited by 598
Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface
Lamb, R. A., Zebedee, S. L., & Richardson, C. D. (1985) · Cell · doi:10.1016/0092-8674(85)90211-9 · Cited by 576
Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain
Steel, J., Lowen, A. C., Wang, T. T., Yondola, M., Gao, Q., Haye, K., García-Sastre, A., & Palese, P. (2010) · mBio · doi:10.1128/mbio.00018-10 · Cited by 533
Kunisaki, K. M., & Janoff, E. N. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70175-6 · Cited by 516
de Jong, J. C., Claas, E. C. J., Osterhaus, A. D. M. E., Webster, R. G., & Lim, W. L. (1997) · Nature · doi:10.1038/39218 · Cited by 497
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
Skowronski, D. M., Janjua, N. Z., De Serres, G., Sabaiduc, S., Eshaghi, A., Dickinson, J. A., Fonseca, K., Winter, A.-L., Gubbay, J. B., Krajden, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092153 · Cited by 416
Partinen, M., Saarenpää-Heikkilä, O., Ilveskoski, I., Hublin, C., Linna, M., Olsén, P., Nokelainen, P., Alén, R., Wallden, T., Espo, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033723 · Cited by 406
Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1
Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L., Collins, K. A., Ewer, K. J., Milicic, A., Poyntz, H. C., Lambe, T., Fletcher, H. A., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq015 · Cited by 384
The rationale for quadrivalent influenza vaccines
Ambrose, C. S., & Levin, M. J. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.17623 · Cited by 376
Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination
Wei, C.-J., Boyington, J. C., McTamney, P. M., Kong, W.-P., Pearce, M. B., Xu, L., Andersen, H., Rao, S., Tumpey, T. M., Yang, Z.-Y., et al. (2010) · Science · doi:10.1126/science.1192517 · Cited by 337
Wang, T. T., Tan, G. S., Hai, R., Pica, N., Ngai, L., Ekiert, D. C., Wilson, I. A., García-Sastre, A., Moran, T. M., & Palese, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013387107 · Cited by 302
Turley, C. B., Rupp, R. E., Johnson, C., Taylor, D. N., Wolfson, J., Tussey, L., Kavita, U., Stanberry, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.041 · Cited by 294
Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
Herzog, C., Hartmann, K., Künzi, V., Kürsteiner, O., Mischler, R., Lazar, H., & Glück, R. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.029 · Cited by 292
Galli, G., Hancock, K., Hoschler, K., DeVos, J., Praus, M., Bardelli, M., Malzone, C., Castellino, F., Gentile, C., McNally, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903181106 · Cited by 263
Wang, Z., Wan, Y., Qiu, C., Quiñones-Parra, S., Zhu, Z., Loh, L., Tian, D., Ren, Y., Hu, Y., Zhang, X., et al. (2015) · Nature Communications · doi:10.1038/ncomms7833 · Cited by 260
Carter, N. J., & Curran, M. P. (2011) · Drugs · doi:10.2165/11206860-000000000-00000 · Cited by 252
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
Cooper, C. L., Davis, H. L., Morris, M. L., Efler, S. M., Krieg, A. M., Li, Y., Laframboise, C., Al Adhami, M. J., Khaliq, Y., Seguin, I., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.01.058 · Cited by 248
Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
Lillie, P. J., Berthoud, T. K., Powell, T. J., Lambe, T., Mullarkey, C., Spencer, A. J., Hamill, M., Peng, Y., Blais, M.-E., Duncan, C. J. A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis327 · Cited by 248
Geeraedts, F., Goutagny, N., Hornung, V., Severa, M., de Haan, A., Pool, J., Wilschut, J., Fitzgerald, K. A., & Huckriede, A. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000138 · Cited by 237
Wijnans, L., Lecomte, C., de Vries, C., Weibel, D., Sammon, C., Hviid, A., Svanström, H., Mølgaard-Nielsen, D., Heijbel, H., Dahlström, L. A., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.015 · Cited by 231
McElhaney, J. E., Zhou, X., Talbot, H. K., Soethout, E., Bleackley, R. C., Granville, D. J., & Pawelec, G. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.015 · Cited by 229
Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice
Hekele, A., Bertholet, S., Archer, J., Gibson, D. G., Palladino, G., Brito, L. A., Otten, G. R., Brazzoli, M., Buccato, S., Bonci, A., et al. (2013) · Emerging Microbes & Infections · doi:10.1038/emi.2013.54 · Cited by 226
Khurana, S., Loving, C. L., Manischewitz, J., King, L. R., Gauger, P. C., Henningson, J., Vincent, A. L., & Golding, H. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006366 · Cited by 223
Recombinant protein vaccines produced in insect cells
Cox, M. M. J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.016 · Cited by 223
T Cell Responses to Viral Infections – Opportunities for Peptide Vaccination
Rosendahl Huber, S., van Beek, J., de Jonge, J., Luytjes, W., & van Baarle, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00171 · Cited by 220
Proietti, E., Bracci, L., Puzelli, S., Di Pucchio, T., Sestili, P., De Vincenzi, E., Venditti, M., Capone, I., Seif, I., De Maeyer, E., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.375 · Cited by 218
Calabro, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., De Gregorio, E., O’Hagan, D. T., Baudner, B., & Seubert, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.007 · Cited by 214
Antrobus, R. D., Coughlan, L., Berthoud, T. K., Dicks, M. D., Hill, A. V., Lambe, T., & Gilbert, S. C. (2014) · Molecular Therapy · doi:10.1038/mt.2013.284 · Cited by 196
Pau, M. G., Ophorst, C., Koldijk, M. H., Schouten, G., Mehtali, M., & Uytdehaag, F. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00508-9 · Cited by 195
Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults
Bernstein, D. I., Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K. B., Graham, I. L., Noah, D. L., He, F., & Hill, H. (2008) · The Journal of Infectious Diseases · doi:10.1086/527489 · Cited by 195
Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments
Schotsaert, M., De Filette, M., Fiers, W., & Saelens, X. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.6 · Cited by 195
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., O'Hagan, D. T., & Podda, A. (2009) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819d6394 · Cited by 190
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
Ledgerwood, J. E., Wei, C.-J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70240-7 · Cited by 188
Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities
Amorij, J.-P., Huckriede, A., Wilschut, J., Frijlink, H. W., & Hinrichs, W. L. J. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9559-6 · Cited by 186
Self-citationA common solution to group 2 influenza virus neutralization
Friesen, R. H. E., Lee, P. S., Stoop, E. J. M., Hoffman, R. M. B., Ekiert, D. C., Bhabha, G., Yu, W., Juraszek, J., Koudstaal, W., Jongeneelen, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319058110 · Cited by 182
Honda-Okubo, Y., Saade, F., & Petrovsky, N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.021 · Cited by 169
A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine
Fries, L. F., Smith, G. E., & Glenn, G. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1313186 · Cited by 167
McElhaney, J. E., Beran, J., Devaster, J.-M., Esen, M., Launay, O., Leroux-Roels, G., Ruiz-Palacios, G. M., van Essen, G. A., Caplanusi, A., Claeys, C., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70046-x · Cited by 164 · cited 1×
“AS03 adjuvanted influenza vaccines were significantly more immunogenic than their unadjuvanted counterparts both in primed and unprimed individuals [79,80].”
BackgroundTree, J. A., Richardson, C., Fooks, A. R., Clegg, J. C., & Looby, D. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00053-6 · Cited by 164
Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization
Brandenburg, B., Koudstaal, W., Goudsmit, J., Klaren, V., Tang, C., Bujny, M. V., Korse, H. J. W. M., Kwaks, T., Otterstrom, J. J., Juraszek, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080034 · Cited by 164
Van Buynder, P. G., Konrad, S., Van Buynder, J. L., Brodkin, E., Krajden, M., Ramler, G., & Bigham, M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.059 · Cited by 160
Gurwith, M., Lock, M. D., Taylor, E. M., Ishioka, G. Y., Alexander, J., Mayall, T., Ervin, J. E., Greenberg, R. N., Strout, C. B., Treanor, J. J., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70345-6 · Cited by 160
Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine
Atsmon, J., Kate-Ilovitz, E., Shaikevich, D., Singer, Y., Volokhov, I., Haim, K. Y., & Ben-Yedidia, T. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9632-5 · Cited by 148
Treanor, J. J., Taylor, D. N., Tussey, L., Hay, C. M., Nolan, C., Fitzgerald, T. F., Liu, G., Kavita, U., Song, L., Dark, I., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.009 · Cited by 148
Smith, L. R., Wloch, M. K., Ye, M., Reyes, L., Boutsaboualoy, S., Dunne, C. E., Chaplin, J. A., Rusalov, D., Rolland, A. P., Fisher, C. L., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.01.029 · Cited by 145
Jones, S. W., Evans, K., McElwaine-Johnn, H., Sharpe, M. E., OXFORD, J. S., Lambkin‐Williams, R., Mant, T., Nolan, A., Zambon, M. C. F. A., Ellis, J., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.061 · Cited by 140
A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine
Cox, R. J., Madhun, A. S., Hauge, S., Sjursen, H., Major, D., Kühne, M., Höschler, K., Saville, M. K., Vogel, F. R., Barclay, W., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.116 · Cited by 140
Rimmelzwaan, G. F., Nieuwkoop, N., Brandenburg, A., Sutter, G., Beyer, W. E., Maher, D., Bates, J., & Osterhaus, A. D. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00310-8 · Cited by 136
Altenburg, A. F., Kreijtz, J. H. C. M., de Vries, R. D., Song, F., Fux, R., Rimmelzwaan, G. F., Sutter, G., & Volz, A. (2014) · Viruses · doi:10.3390/v6072735 · Cited by 135
Taylor, D. N., Treanor, J. J., Sheldon, E. A., Johnson, C., Umlauf, S., Song, L., Kavita, U., Liu, G., Tussey, L., Ozer, K., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.086 · Cited by 132
Seasonal influenza: The burden of disease in children
Fraaij, P. L. A., & Heikkinen, T. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.010 · Cited by 130
Needle-free influenza vaccination
Amorij, J., Hinrichs, W. L. J., Frijlink, H. W., Wilschut, J., & Huckriede, A. L. W. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70157-2 · Cited by 128
Self-citationAntrobus, R., Lillie, P. J., Berthoud, T. K., Spencer, A. J., McLaren, J. E., Ladell, K., Lambe, T., Milicic, A., Price, D. A., Hill, A. V. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048322 · Cited by 128
Trivalent MDCK cell culture-derived influenza vaccine Optaflu®(Novartis Vaccines)
Doroshenko, A., & Halperin, S. A. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.31 · Cited by 126
Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults
Barría, M. I., Garrido, J. L. V., Stein, C. R., Scher, E., Ge, Y., Engel, S. M., Kraus, T., Banach, D. B., & Moran, T. M. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis641 · Cited by 114
Multiple Redundant Effector Mechanisms of CD8+ T Cells Protect against Influenza Infection
Hamada, H., Bassity, E., Flies, A., Strutt, T. M., García-Hernández, M. D. L. L., McKinstry, K. K., Zou, T., Swain, S. L., & Dutton, R. W. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200571 · Cited by 111
Gordon, D., Sajkov, D., Woodman, R. J., Honda‐Okubo, Y., Cox, M. M. J., Heinzel, S., & Petrovsky, N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.009 · Cited by 110
Amorij, J.-P., Meulenaar, J., Hinrichs, W. L. J., Stegmann, T., Huckriede, A. L. W., Coenen, F., & Frijlink, H. W. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.054 · Cited by 109
Self-citationEnnis, F. A., Cruz, J., Jameson, J., Klein, M. H., Burt, D. S., & Thipphawong, J. (1999) · Virology · doi:10.1006/viro.1999.9765 · Cited by 109
Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing
Ru, A. L., Jacob, D., Transfiguracion, J. C., Ansorge, S., Henry, O., & Kamen, A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.029 · Cited by 107
Beyer, W. E. P., Palache, A. M., & Osterhaus, A. D. M. E. (1998) · Clinical Drug Investigation · doi:10.2165/00044011-199815010-00001 · Cited by 107
Joseph, A., Itskovitz-Cooper, N., Samira, S., Flasterstein, O., Eliyahu, H., Simberg, D., Goldwaser, I., Barenholz, Y., & Kedar, E. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.12.017 · Cited by 105
Towards tailored vaccine delivery: Needs, challenges and perspectives
Amorij, J., Kersten, G. F. A., Saluja, V., Tonnis, W. F., Hinrichs, W. L. J., Slütter, B., Bal, S. M., Bouwstra, J. A., Huckriede, A. L. W., & Jiskoot, W. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.039 · Cited by 104
Self-citationAntrobus, R., Berthoud, T. K., Mullarkey, C. E., Höschler, K., Coughlan, L., Zambon, M. C. F. A., Hill, A. V. S., & Gilbert, S. C. (2013) · Molecular Therapy · doi:10.1038/mt.2013.162 · Cited by 104
Cox, R. J., Pedersen, G. K., Madhun, A. S., Svindland, S. C., Sævik, M., Breakwell, L., Höschler, K., Willemsen, M., Campitelli, L., Nøstbakken, J. K., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.042 · Cited by 103
Self-citationFriesen, R. H. E., Koudstaal, W., Koldijk, M. H., Weverling, G. J., Brakenhoff, J. P. J., Lenting, P. J., Stittelaar, K. J., Osterhaus, A. D. M. E., Kompier, R., & Goudsmit, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009106 · Cited by 103
Self-citationMeta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines
Manzoli, L., Vito, C. D., Salanti, G., D’Addario, M., Villari, P., & Ioannidis, J. P. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024384 · Cited by 98
Li, I. W. S., Chan, K., To, K. K., Wong, S. S. Y., Ho, P., Lau, S.-Y., Woo, P. C. Y., Tsoi, H., Chan, J. F., Cheng, V. C., et al. (2009) · Journal of Clinical Virology · doi:10.1016/j.jcv.2009.09.013 · Cited by 97
Vaarala, O., Vuorela, A., Partinen, M., Baumann, M., Freitag, T. L., Meri, S., Saavalainen, P., Jauhiainen, M., Soliymani, R., Kirjavainen, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114361 · Cited by 97
Squarcione, S., Sgricia, S., Biasio, L. R., & Perinetti, E. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00401-2 · Cited by 97
On the structure of immune-stimulating saponin-lipid complexes (iscoms)
Kersten, G. F. A., Spiekstra, A., Beuvery, E. C., et al. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90388-o · Cited by 96
Self-citationTreanor, J. J., Essink, B. J., Hull, S. G., Reed, S. G., Izikson, R., PATRIARCA, P. A., Goldenthal, K. L., Kohberger, R. C., & Dunkle, L. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.064 · Cited by 89
Atsmon, J., Caraco, Y., Ziv-Sefer, S., Shaikevich, D., Abramov, E., Volokhov, I., Bruzil, S., Haima, K. Y., Gottlieb, T. M., & Ben-Yedidia, T. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.031 · Cited by 88
Ninomiya, A., Ogasawara, K., Kajino, K., Takada, A., & Kida, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00261-x · Cited by 86
Pleguezuelos, O., Robinson, S., Stoloff, G. A., & Caparrós‐Wanderley, W. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.089 · Cited by 85
Schneemann, A., Speir, J. A., Tan, G. S., Khayat, R., Ekiert, D. C., Matsuoka, Y., & Wilson, I. A. (2012) · Journal of Virology · doi:10.1128/jvi.01694-12 · Cited by 82
Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine
Kopecky-Bromberg, S. A., Fraser, K. A., Pica, N., Carnero, E., Moran, T. M., Franck, R. W., Tsuji, M., & Palese, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.090 · Cited by 81
Antibody responses after dose-sparing intradermal influenza vaccination
Auewarakul, P., Kositanont, U., Sornsathapornkul, P., Tothong, P., Kanyok, R., & D, P. T. M. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.026 · Cited by 79
Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes
Arkema, A., Huckriede, A. L. W., Schoen, P., Wilschut, J., & Daemen, T. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00404-1 · Cited by 77
Loudon, P. T., Yager, E. J., Lynch, D. T., Narendran, A., Stagnar, C., Franchini, A. M., Fuller, J. T., White, P., Nyuandi, J., Wiley, C. A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011021 · Cited by 76
Beyer, W. E. P., Nauta, J. J. P., Palache, A. M., Giezeman‐Smits, K. M., & Osterhaus, A. D. M. E. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.040 · Cited by 74
King, J. C., Cox, M. M. J., Reisinger, K. S., HEDRICK, J. A., Graham, I. L., & PATRIARCA, P. A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.08.032 · Cited by 72
Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines
Hess, R. D., Weber, F., Watson, K., & Schmitt, S. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.015 · Cited by 69
Host Immune Responses to Chronic Adenovirus Infections in Human and Nonhuman Primates
Calcedo, R., Vandenberghe, L. H., Roy, S., Somanathan, S., Wang, L., & Wilson, J. M. (2008) · Journal of Virology · doi:10.1128/jvi.02160-08 · Cited by 68
Layton, R. C., Petrovsky, N., Gigliotti, A. P., Pollock, Z. E., Knight, J. B., Donart, N., Pyles, J. A., Harrod, K. S., Gao, P., & Koster, F. T. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.078 · Cited by 66
Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with Previous Influenza Exposure
Wei, C., Yassine, H. M., McTamney, P. M., Gall, J. G. D., Whittle, J. R. R., Boyington, J. C., & Nabel, G. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004273 · Cited by 64
Ichinohe, T., Ainai, A., Tashiro, M., Sata, T., & Hasegawa, H. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.074 · Cited by 63
DNA vaccine manufacture: scale and quality
Cai, Y., Rodriguez, S. A., & Hebel, H. L. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.84 · Cited by 62
Francis, J. N., Bunce, C., Horlock, C., Watson, J. M., Warrington, S., Georges, B., & Brown, C. B. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.06.006 · Cited by 62
Flu Myths: Dispelling the Myths Associated With Live Attenuated Influenza Vaccine
Tosh, P. K., Boyce, T. G., & Poland, G. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.1.77 · Cited by 57
Riedl, K., Riedl, R., von Gabain, A., Nagy, E., & Lingnau, K. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.029 · Cited by 54
Development of Cross-Protective Influenza A Vaccines Based on Cellular Responses
Soema, P. C., van Riet, E., Kersten, G. F. A., & Amorij, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00237 · Cited by 52
Self-citationJacob, L., Leib, R. D., Ollila, H. M., Bonvalet, M., Adams, C. M., & Mignot, E. J.-M. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.11.004 · Cited by 52
Mbawuike, I. N., Zang, Y., & Couch, R. B. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.073 · Cited by 50
Pérez-Girón, J. V., Belicha‐Villanueva, A., Hassan, E., Gómez‐Medina, S., Cruz, J. L. G., Lüdtke, A., Ruibal, P., Albrecht, R. A., García‐Sastre, A., & Muñoz‐Fontela, C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400222 · Cited by 49
Babin, C., Majeau, N., & Leclerc, D. (2013) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-11-10 · Cited by 48
CAP, a new human suspension cell line for influenza virus production
Genzel, Y., Behrendt, I., Rödig, J., Rapp, E., Kueppers, C., Kochanek, S., Schiedner, G., & Reichl, U. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4238-2 · Cited by 46
Ichihashi, T., Yoshida, R., Sugimoto, C., Takada, A., & Kajino, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024626 · Cited by 45
Even‐Or, O., Joseph, A., Itskovitz-Cooper, N., Samira, S., Rochlin, E., Eliyahu, H., Goldwaser, I., Balasingam, S., Mann, A., & Lambkin‐Williams, R. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.009 · Cited by 41
Clemens, E. B., Zeng, W., Doherty, P. C., Jackson, D. C., Kedzierska, K., & Turner, S. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2187 · Cited by 41
Cioppa, G. D., Vesikari, T., Sokal, E. M., LINDERT, K. A., & Nicolay, U. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.111 · Cited by 39
Brignone, C., Grygar, C., Marcu, M., Perrin, G., & Triebel, F. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.019 · Cited by 37
Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes
Sawaengsak, C., Mori, Y., Yamanishi, K., Srimanote, P., Chaicumpa, W., Mitrevej, A., & Sinchaipanid, N. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.07.005 · Cited by 37
Ma, J.-H., Yang, F.-R., Yu, H., Zhou, Y., Li, G., Huang, M., Wen, F., & Tong, G. (2013) · Virology Journal · doi:10.1186/1743-422x-10-227 · Cited by 36
Mann, A., Noulin, N., Catchpole, A. P., Stittelaar, K. J., de Waal, L., Kroeze, E. J. B. V., Hinchcliffe, M., Smith, A., Montomoli, E., Piccirella, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093761 · Cited by 34
Matsui, M., Kohyama, S., Suda, T., Yokoyama, S., Mori, M., Kobayashi, A., Taneichi, M., & Uchida, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.100 · Cited by 33
Ansaldi, F., de Florentiis, D., Durando, P., & Icardi, G. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.154 · Cited by 33
Live Attenuated Vaccines for Pandemic Influenza
Chen, G. L., & Subbarao, K. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-92165-3_5 · Cited by 32
Ichihashi, T., Satoh, T., Sugimoto, C., & Kajino, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060068 · Cited by 32
CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets
Martel, C. J., Agger, E. M., Poulsen, J. J., Jensen, T. H., Andresen, L. O., Christensen, D., Nielsen, L. P., Blixenkrone-Møller, M., Andersen, P. L., & Aasted, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022891 · Cited by 31
A cell-based backup to speed up pandemic influenza vaccine production
Lee, M.-S., & Hu, A. Y.-C. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2011.12.002 · Cited by 28
Glenn, G. M., Thomas, D. N., Poffenberger, K. L., Flyer, D. C., Ellingsworth, L. R., Andersen, B. H., & Frech, S. A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.031 · Cited by 25
van Els, C. A. C. M., Mjaaland, S., Næss, L. M., Sarkadi, J., Gönczöl, É., Korsholm, K. S., Hansen, J. U., de Jonge, J., Kersten, G. F. A., Warner, J., et al. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28639 · Cited by 20
Self-citationLiposome-Coupled Peptides Induce Long-Lived Memory CD8+ T Cells Without CD4+ T Cells
Taneichi, M., Tanaka, Y., Kakiuchi, T., & Uchida, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015091 · Cited by 18
Soema, P. C., Willems, G.-J., van Twillert, K., van de Wijdeven, G. G. P., Boog, C. J. P., Kersten, G. F. A., & Amorij, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092806 · Cited by 16
Self-citationKhan, T., Heffron, C. L., High, K. P., & Roberts, P. C. (2014) · Virology Journal · doi:10.1186/1743-422x-11-78 · Cited by 13
Smith, L. R., Wodal, W., Crowe, B. A., Kerschbaum, A., Bruehl, P., Schwendinger, M. G., Savidis-Dacho, H., Sullivan, S. M., Shlapobersky, M., Hartikka, J., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24209 · Cited by 10
Cited by
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Understanding modern-day vaccines: what you need to know
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. (2018) · Annals of Medicine · doi:10.1080/07853890.2017.1407035 · Cited by 354
Next-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Biological sex affects vaccine efficacy and protection against influenza in mice
Fink, A. L., Engle, K., Ursin, R. L., Tang, W.-Y., & Klein, S. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805268115 · Cited by 253
Metadata
- Authors
- Soema, P. C., Kompier, R., Amorij, J.-P., & Kersten, G. F. A.
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 94
- Pages
- 251-263
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W591557396
- Cited by
- 314
- References
- 123
- FWCI
- 19.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.